Tego Science, Inc. Logo

Tego Science, Inc.

Develops cell therapies for skin regeneration, 3D models for testing, and provides CDMO services.

191420 | KO

Overview

Corporate Details

ISIN(s):
KR7191420009
LEI:
Country:
South Korea
Address:
서울특별시 강서구 마곡중앙8로 93 (마곡동, 테고사이언스), 서울특별시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Tego Science, Inc. is a biopharmaceutical company specializing in advanced regenerative medicine, leveraging proprietary cell culture technology. Founded in 2001, the company develops, manufactures, and commercializes cell therapies for skin regeneration and wound healing. Its key approved products include Holoderm® for severe burns, Kaloderm® for diabetic foot ulcers, and Rosmir® for wrinkle improvement. Beyond therapeutics, Tego Science offers Neoderm®, a 3D cultured skin model as an alternative to animal testing, and provides Contract Development and Manufacturing Organization (CDMO) services from its GMP facility. The company maintains a robust R&D pipeline, with candidates like TPX-115 for rotator cuff tears, and operates a globally compliant allogeneic cell bank to ensure stable production of its innovative treatments.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 1.1 MB
2025-05-27 00:00
Share Issue/Capital Change
증권발행결과(자율공시)
Korean 5.6 KB
2025-05-26 00:00
Capital/Financing Update
[기재정정]주요사항보고서(전환사채권발행결정)
Korean 111.0 KB
2025-05-23 00:00
Capital/Financing Update
주요사항보고서(전환사채권발행결정)
Korean 108.1 KB
2025-05-14 00:00
Quarterly Report
분기보고서 (2025.03)
Korean 1.1 MB
2025-03-28 00:00
Post-Annual General Meeting Information
정기주주총회결과
Korean 23.1 KB
2025-03-19 00:00
Audit Report / Information
감사보고서제출
Korean 25.0 KB
2025-03-19 00:00
Annual Report
사업보고서 (2024.12)
Korean 1.4 MB
2025-03-06 00:00
Pre-Annual General Meeting Information
주주총회소집결의
Korean 12.2 KB
2025-03-06 00:00
Pre-Annual General Meeting Information
주주총회소집공고
Korean 134.4 KB
2025-03-06 00:00
Pre-Annual General Meeting Information
주주총회집중일개최사유신고
Korean 4.4 KB
2025-03-06 00:00
Pre-Annual General Meeting Information
[기재정정]주주총회소집공고
Korean 138.0 KB
2025-02-14 00:00
Report Publication Announcement
기업설명회(IR)개최
Korean 6.9 KB
2025-02-14 00:00
Regulatory News Service
투자판단관련주요경영사항(임상시험계획승인신청등결정) (회전근개 부분층 파열 개선을 위한 동종피부유래섬유아세포(TPX-11…
Korean 10.2 KB
2025-01-31 00:00
Regulatory News Service
매출액또는손익구조30%(대규모법인은15%)이상변동
Korean 11.0 KB

Automate Your Workflow. Get a real-time feed of all Tego Science, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Tego Science, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Tego Science, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

NuCana plc Logo
Develops safer anti-cancer medicines with ProTide technology to overcome cell resistance.
United States of America
NCNA
NUFORMIX PLC Logo
Repurposing drugs for fibrosis and oncology using proprietary cocrystal technology.
United Kingdom
NFX
Nurix Therapeutics, Inc. Logo
Developing protein degradation medicines to treat cancer and autoimmune diseases.
United States of America
NRIX
NUTEX Investments Plc Logo
Develops & distributes health, cosmetic & pharma products from natural ingredients globally.
Hungary
NUTEX
NutriBand Inc. Logo
Develops abuse-deterrent transdermal patches to make potent drug delivery safer.
United States of America
NTRB
Nuvalent, Inc. Logo
Designs targeted small molecule drugs for kinase-driven cancers to overcome treatment resistance.
United States of America
NUVL
Nuvation Bio Inc. Logo
A clinical-stage biopharma developing novel drugs for difficult-to-treat cancers.
United States of America
NUVB
Nxera Pharma Co., Ltd. Logo
Biopharma using SBDD tech to develop medicines for neurology and gastroenterology.
Japan
4565
ObsEva SA Logo
Developed novel therapeutics for women's reproductive health and pregnancy.
Switzerland
OBSN
OCULAR THERAPEUTIX, INC Logo
Develops hydrogel drug delivery therapies for eye diseases like wet AMD and glaucoma.
United States of America
OCUL

Talk to a Data Expert

Have a question? We'll get back to you promptly.